{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:26:39Z","timestamp":1787840799021,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Overweight and obesity are common in patients with psoriasis and are associated with increased disease severity and declined treatment response.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n \n To evaluate the short-to-medium term (24w) efficacy and safety of two biologics, including Guselkumab and Secukinumab, in overweight and obese patients (body mass index [BMI] \u226525 kg\/m\n 2<\/jats:sup>\n ) with moderate to severe psoriasis.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n We retrospectively analyzed the data of patients with moderate to severe plaque psoriasis treated with Guselkumab or Secukinumab in Dermatology Hospital of Southern Medical University in 2020. Totally 34 and 67 patients were treated with Guselkumab and Secukinumab, respectively; the patient groups with BMI \u226525 kg\/m\n 2<\/jats:sup>\n comprised 16 and 33 cases, respectively. Baseline demographics and clinical characteristics were recorded, and Psoriasis Area and Severity Index (PASI) scores, adverse events, and biochemical parameters were assessed at weeks 12, 16, and 24.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Both Guselkumab and Secukinumab demonstrated good clinical efficacy. In patients with BMI \u226525 kg\/m\n 2<\/jats:sup>\n , there was a higher percentage of cases achieving PASI 100 at week 16 in the Secukinumab group; however, at week 24, the proportion of patients treated with Guselkumab achieving PASI 100 was significantly higher than that of cases treated with Secukinumab (\n P<\/jats:italic>\n = 0.037 and\n P<\/jats:italic>\n < 0.001, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n Guselkumab and Secukinumab demonstrated good short-to-medium-term efficacy in Chinese patients with moderate to severe plaque psoriasis. In patients with a BMI \u226525 kg\/m\n 2<\/jats:sup>\n , Secukinumab demonstrated a faster onset of efficacy, while Guselkumab demonstrated significantly higher efficacy at week 24.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijd.ijd_663_23","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T07:00:09Z","timestamp":1754377209000},"page":"252-256","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study"],"prefix":"10.4103","volume":"70","author":[{"given":"Xiuqiu","family":"Lin","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China"},{"name":"Department of Dermatology, Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huizhou Dermatology Hospital, Huizhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dermatology Hospital of Fuzhou, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunling","family":"Yan","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"R1-20251031","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis:Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"R2-20251031","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1684\/ejd.2012.1802","article-title":"Prevalence of psoriasis in China:A population-based study in six cities","volume":"22","author":"Ding","year":"2012","journal-title":"Eur J Dermatol"},{"key":"R3-20251031","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bjd.16885","article-title":"Metabolic syndrome and risk of incident psoriasis:Prospective data from the HUNT Study, Norway","volume":"180","author":"Snekvik","year":"2019","journal-title":"Br J Dermatol"},{"key":"R4-20251031","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10654-018-0366-z","article-title":"Body mass index, abdominal fatness, weight gain and the risk of psoriasis:A systematic review and dose-response meta-analysis of prospective studies","volume":"33","author":"Aune","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"R5-20251031","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/life11121316","article-title":"Body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis","volume":"11","author":"Anghel","year":"2021","journal-title":"Life"},{"key":"R6-20251031","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14740338.2019.1663168","article-title":"The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis","volume":"18","author":"D'Adamio","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"R7-20251031","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus Secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE):Results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"R8-20251031","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s13555-021-00581-1","article-title":"Secukinumab demonstrated high effectiveness in Vietnamese patients with moderate-to-severe plaque psoriasis in a real-world clinical setting:16 week results from an observational study","volume":"11","author":"Nguyen","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R9-20251031","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/09546634.2021.1959504","article-title":"Efficacy of Guselkumab versus Secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis:Results from the ECLIPSE study","volume":"33","author":"Blauvelt","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"R10-20251031","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of body mass index on the efficacy of biological therapies in patients with psoriasis:A real-world study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin Drug Invest"},{"key":"R11-20251031","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol"},{"key":"R12-20251031","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"R13-20251031","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/1389450116666150531153627","article-title":"IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression","volume":"16","author":"Giles","year":"2015","journal-title":"Curr Drug Targets"},{"key":"R14-20251031","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13679-020-00380-3","article-title":"Deciphering the association between psoriasis and obesity:Current evidence and treatment considerations","volume":"9","author":"Paroutoglou","year":"2020","journal-title":"Curr Obes Rep"},{"issue":"(Suppl 1)","key":"R15-20251031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000501990","article-title":"Secukinumab for psoriasis in obese patients:Minireview and clinical experience","volume":"11","author":"Tiberio","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"R16-20251031","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/1346-8138.14526","article-title":"Effects of tumor necrosis factor-alpha, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis","volume":"45","author":"Takamura","year":"2018","journal-title":"J Dermatol"},{"key":"R17-20251031","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/jcm9072170","article-title":"Use of Guselkumab for the treatment of moderate-to-severe plaque psoriasis:A 1 year real-life study","volume":"9","author":"Galluzzo","year":"2020","journal-title":"J Clin Med"},{"key":"R18-20251031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1755-148X.2011.00945.x","article-title":"Dysregulation of melanocyte function by Th17-related cytokines:Significance of Th17 cell infiltration in autoimmune vitiligo vulgaris","volume":"25","author":"Kotobuki","year":"2012","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_663_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:29:15Z","timestamp":1787837355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_663_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_663_23","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}